论文部分内容阅读
目的探讨血清可溶性细胞间黏附分子-1/血管细胞黏附分子-1(sICAM-1/sVCAM-1)在上皮性卵巢癌中的临床意义。方法利用ELISA法检测健康妇女血清sICAM-1/sVCAM-1浓度并确定其血清正常值范围。同时测定良性卵巢肿瘤和上皮性卵巢癌患者血清sICAM-1/sVCAM-1浓度并分析其与上皮性卵巢癌患者临床病理资料的关系。结果血清sICAM-1和sVCAM-1平均浓度和阳性率卵巢上皮癌组显著高于良性卵巢瘤组和正常对照组(P<0.05);临床Ⅱ~Ⅳ期显著高于临床I期卵巢癌患者(P<0.05);淋巴结转移阳性者显著高于淋巴结转移阴性者(P<0.01);组织分化程度Ⅲ级显著高于I、Ⅱ级(P<0.01);卵巢癌组术后显著低于术前(P<0.005)。而sICAM-1和sVCAM-1浓度和阳性率与卵巢癌病理组织学类型无关。单因素生存分析sICAM-1和sVCAM-1水平与患者不良预后有关;多因素生存分析sICAM-1和sVCAM-1水平与预后无关。结论sICAM-1/sVCAM-1检测可能有助于监测和判断上皮性卵巢癌患者的病情。
Objective To investigate the clinical significance of serum soluble intercellular adhesion molecule-1 / sVCAM-1 in epithelial ovarian cancer. Methods Serum levels of sICAM-1 / sVCAM-1 in healthy women were determined by ELISA and their serum normal range was determined. The serum concentrations of sICAM-1 / sVCAM-1 in patients with benign ovarian tumors and epithelial ovarian cancer were determined at the same time and analyzed the relationship with the clinicopathological data of patients with epithelial ovarian cancer. Results The average concentration and positive rate of serum sICAM-1 and sVCAM-1 in ovarian epithelial cancer group were significantly higher than those in benign ovarian tumor group and normal control group (P <0.05). The clinical stage Ⅱ ~ Ⅳ was significantly higher than that in clinical stage Ⅰ ovarian cancer P <0.05). The positive rate of lymph node metastasis was significantly higher than that of negative lymph node metastasis (P <0.01). The grade of differentiation was significantly higher than that of grade I and II (P <0.01) (P <0.005). However, the concentration and positive rate of sICAM-1 and sVCAM-1 were not related to the histopathological types of ovarian cancer. Univariate survival analysis sICAM-1 and sVCAM-1 levels and poor prognosis of patients; multivariate survival analysis sICAM-1 and sVCAM-1 levels have nothing to do with the prognosis. Conclusion The detection of sICAM-1 / sVCAM-1 may be helpful for monitoring and judging the condition of epithelial ovarian cancer patients.